200 related articles for article (PubMed ID: 19860657)
1. AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS.
Hester ME; Foust KD; Kaspar RW; Kaspar BK
Curr Gene Ther; 2009 Oct; 9(5):428-33. PubMed ID: 19860657
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.
Wang LJ; Lu YY; Muramatsu S; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Matsushita T; Hanazono Y; Kume A; Nagatsu T; Ozawa K; Nakano I
J Neurosci; 2002 Aug; 22(16):6920-8. PubMed ID: 12177190
[TBL] [Abstract][Full Text] [Related]
3. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors.
Miyake N; Miyake K; Yamamoto M; Hirai Y; Shimada T
Brain Res; 2011 May; 1389():19-26. PubMed ID: 21397590
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy for ALS-A Perspective.
Cappella M; Ciotti C; Cohen-Tannoudji M; Biferi MG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500113
[TBL] [Abstract][Full Text] [Related]
5. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.
Nizzardo M; Simone C; Falcone M; Riboldi G; Rizzo F; Magri F; Bresolin N; Comi GP; Corti S
Cell Mol Life Sci; 2012 May; 69(10):1641-50. PubMed ID: 22094924
[TBL] [Abstract][Full Text] [Related]
6. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
[TBL] [Abstract][Full Text] [Related]
7. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.
Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL
Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242
[TBL] [Abstract][Full Text] [Related]
8. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons.
Yamashita T; Chai HL; Teramoto S; Tsuji S; Shimazaki K; Muramatsu S; Kwak S
EMBO Mol Med; 2013 Nov; 5(11):1710-9. PubMed ID: 24115583
[TBL] [Abstract][Full Text] [Related]
9. Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives.
Ediriweera GR; Chen L; Yerbury JJ; Thurecht KJ; Vine KL
Mol Pharm; 2021 Jun; 18(6):2142-2160. PubMed ID: 34010004
[TBL] [Abstract][Full Text] [Related]
10. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection.
Huang L; Wan J; Wu Y; Tian Y; Yao Y; Yao S; Ji X; Wang S; Su Z; Xu H
Life Sci; 2021 Apr; 270():119142. PubMed ID: 33524419
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated delivery of glial cell line-derived neurotrophic factor protects motor neuron-like cells from apoptosis.
Keir SD; Xiao X; Li J; Kennedy PG
J Neurovirol; 2001 Oct; 7(5):437-46. PubMed ID: 11582516
[TBL] [Abstract][Full Text] [Related]
12. GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease.
Li K; Hala TJ; Seetharam S; Poulsen DJ; Wright MC; Lepore AC
Neurobiol Dis; 2015 Jun; 78():12-23. PubMed ID: 25818008
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors.
Merjane J; Chung R; Patani R; Lisowski L
Med Res Rev; 2023 Jul; 43(4):829-854. PubMed ID: 36786126
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis after transplantation of human umbilical cord blood cells genetically modified with adeno-viral vectors expressing a neuro-protective factor and a neural cell adhesion molecule.
Islamov RR; Rizvanov AA; Mukhamedyarov MA; Salafutdinov II; Garanina EE; Fedotova VY; Solovyeva VV; Mukhamedshina YO; Safiullov ZZ; Izmailov AA; Guseva DS; Zefirov AL; Kiyasov AP; Palotas A
Curr Gene Ther; 2015; 15(3):266-76. PubMed ID: 25619885
[TBL] [Abstract][Full Text] [Related]
15. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease.
Bucher T; Colle MA; Wakeling E; Dubreil L; Fyfe J; Briot-Nivard D; Maquigneau M; Raoul S; Cherel Y; Astord S; Duque S; Marais T; Voit T; Moullier P; Barkats M; Joussemet B
Hum Gene Ther; 2013 Jul; 24(7):670-82. PubMed ID: 23799774
[TBL] [Abstract][Full Text] [Related]
16. Crossing the blood-brain barrier with AAV vectors.
Liu D; Zhu M; Zhang Y; Diao Y
Metab Brain Dis; 2021 Jan; 36(1):45-52. PubMed ID: 33201426
[TBL] [Abstract][Full Text] [Related]
17. More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose-response and comparison to AAV PHP.B.
Dayton RD; Grames MS; Klein RL
Gene Ther; 2018 Aug; 25(5):392-400. PubMed ID: 30013186
[TBL] [Abstract][Full Text] [Related]
18. AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials.
Hardcastle N; Boulis NM; Federici T
Expert Opin Biol Ther; 2018 Mar; 18(3):293-307. PubMed ID: 29249183
[TBL] [Abstract][Full Text] [Related]
19. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.
Franz CK; Federici T; Yang J; Backus C; Oh SS; Teng Q; Carlton E; Bishop KM; Gasmi M; Bartus RT; Feldman EL; Boulis NM
Neurobiol Dis; 2009 Mar; 33(3):473-81. PubMed ID: 19135533
[TBL] [Abstract][Full Text] [Related]
20. Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.
Choudhury SR; Harris AF; Cabral DJ; Keeler AM; Sapp E; Ferreira JS; Gray-Edwards HL; Johnson JA; Johnson AK; Su Q; Stoica L; DiFiglia M; Aronin N; Martin DR; Gao G; Sena-Esteves M
Mol Ther; 2016 Apr; 24(4):726-35. PubMed ID: 26708003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
